Hematological malignancies encompass a diverse range of diseases, such as leukemia, lymphoma, and multiple myeloma, among others. Within the multidisciplinary treatment approach, radiation therapy ...

Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.

Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

Recent regulatory actions from the FDA, including new drug application (NDA) acceptances and labeling updates, introduce new clinical considerations for oncology nurses and advanced practice providers ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...

India, Feb. 18 -- Indian film actress Pravina Deshpande, who featured in Ready starring Salman Khan and had a long run in TV ...

The FDA has accepted Bristol Myers Squibb (BMS)’s New Drug Application (NDA) for iberdomide for relapsed or refractory ...

Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...